vTv Therapeutics (VTVT) Equity Ratio (2014 - 2026)

vTv Therapeutics has disclosed Equity Ratio across 13 years of filings, most recently posting 0.91 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.91, up 227.72% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.91 (up 227.72% YoY), and the FY2025 annual result was 0.72, up 91.79% from the prior year.
• Equity Ratio came in at 0.91 for Q1 2026 at vTv Therapeutics, up from 0.72 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.91 in Q1 2026 to a low of 2.24 in Q4 2023.
• The 5-year median for Equity Ratio is 0.09 (2025), against an average of 0.16.
• Across the five-year window, Equity Ratio sank 593.22% in 2023 and surged 227.72% in 2026, its largest moves.
• vTv Therapeutics' Equity Ratio stood at 0.32 in 2022, then tumbled by 593.22% to 2.24 in 2023, then soared by 116.68% to 0.37 in 2024, then surged by 91.79% to 0.72 in 2025, then advanced by 27.01% to 0.91 in 2026.
• The last three Equity Ratio figures came in at 0.91 (Q1 2026), 0.72 (Q4 2025), and 0.71 (Q3 2025), per Business Quant data.